104 related articles for article (PubMed ID: 20104563)
1. Toward a consensus model of the HERG potassium channel.
Stary A; Wacker SJ; Boukharta L; Zachariae U; Karimi-Nejad Y; Aqvist J; Vriend G; de Groot BL
ChemMedChem; 2010 Mar; 5(3):455-67. PubMed ID: 20104563
[TBL] [Abstract][Full Text] [Related]
2. A novel structure-based virtual screening model for the hERG channel blockers.
Du L; Li M; You Q; Xia L
Biochem Biophys Res Commun; 2007 Apr; 355(4):889-94. PubMed ID: 17331468
[TBL] [Abstract][Full Text] [Related]
3. Interaction simulation of hERG K+ channel with its specific BeKm-1 peptide: insights into the selectivity of molecular recognition.
Yi H; Cao Z; Yin S; Dai C; Wu Y; Li W
J Proteome Res; 2007 Feb; 6(2):611-20. PubMed ID: 17269718
[TBL] [Abstract][Full Text] [Related]
4. Analogs of MK-499 are differentially affected by a mutation in the S6 domain of the hERG K+ channel.
Karczewski J; Wang J; Kane SA; Kiss L; Koblan KS; Culberson JC; Spencer RH
Biochem Pharmacol; 2009 May; 77(10):1602-11. PubMed ID: 19426697
[TBL] [Abstract][Full Text] [Related]
5. Modeling the hERG potassium channel in a phospholipid bilayer: Molecular dynamics and drug docking studies.
Masetti M; Cavalli A; Recanatini M
J Comput Chem; 2008 Apr; 29(5):795-808. PubMed ID: 17926340
[TBL] [Abstract][Full Text] [Related]
6. Molecular dynamics and continuum electrostatics studies of inactivation in the HERG potassium channel.
Kutteh R; Vandenberg JI; Kuyucak S
J Phys Chem B; 2007 Feb; 111(5):1090-8. PubMed ID: 17266262
[TBL] [Abstract][Full Text] [Related]
7. Docking model of drug binding to the human ether-à-go-go potassium channel guided by tandem dimer mutant patch-clamp data: a synergic approach.
Imai YN; Ryu S; Oiki S
J Med Chem; 2009 Mar; 52(6):1630-8. PubMed ID: 19260734
[TBL] [Abstract][Full Text] [Related]
8. 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD-307243) causes instantaneous current through human ether-a-go-go-related gene potassium channels.
Gordon E; Lozinskaya IM; Lin Z; Semus SF; Blaney FE; Willette RN; Xu X
Mol Pharmacol; 2008 Mar; 73(3):639-51. PubMed ID: 18042732
[TBL] [Abstract][Full Text] [Related]
9. Block of the hERG channel by bupivacaine: Electrophysiological and modeling insights towards stereochemical optimization.
Sintra Grilo L; Carrupt PA; Abriel H; Daina A
Eur J Med Chem; 2011 Aug; 46(8):3486-98. PubMed ID: 21624711
[TBL] [Abstract][Full Text] [Related]
10. Molecular determinants of hERG channel block by terfenadine and cisapride.
Kamiya K; Niwa R; Morishima M; Honjo H; Sanguinetti MC
J Pharmacol Sci; 2008 Nov; 108(3):301-7. PubMed ID: 18987434
[TBL] [Abstract][Full Text] [Related]
11. Insights for human ether-a-go-go-related gene potassium channel inhibition using recursive partitioning and Kohonen and Sammon mapping techniques.
Ekins S; Balakin KV; Savchuk N; Ivanenkov Y
J Med Chem; 2006 Aug; 49(17):5059-71. PubMed ID: 16913696
[TBL] [Abstract][Full Text] [Related]
12. [HERG K+ channel, the target of anti-arrhythmias drugs].
Guan FY; Yang SJ
Yao Xue Xue Bao; 2007 Jul; 42(7):687-91. PubMed ID: 17882949
[TBL] [Abstract][Full Text] [Related]
13. Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.
Zachariae U; Giordanetto F; Leach AG
J Med Chem; 2009 Jul; 52(14):4266-76. PubMed ID: 19534531
[TBL] [Abstract][Full Text] [Related]
14. Physicochemical features of the HERG channel drug binding site.
Fernandez D; Ghanta A; Kauffman GW; Sanguinetti MC
J Biol Chem; 2004 Mar; 279(11):10120-7. PubMed ID: 14699101
[TBL] [Abstract][Full Text] [Related]
15. New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies.
Farid R; Day T; Friesner RA; Pearlstein RA
Bioorg Med Chem; 2006 May; 14(9):3160-73. PubMed ID: 16413785
[TBL] [Abstract][Full Text] [Related]
16. Topological mapping of the asymmetric drug binding to the human ether-à-go-go-related gene product (HERG) potassium channel by use of tandem dimers.
Myokai T; Ryu S; Shimizu H; Oiki S
Mol Pharmacol; 2008 Jun; 73(6):1643-51. PubMed ID: 18326583
[TBL] [Abstract][Full Text] [Related]
17. A composite model for HERG blockade.
Kramer C; Beck B; Kriegl JM; Clark T
ChemMedChem; 2008 Feb; 3(2):254-65. PubMed ID: 18061919
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of the first sulfur-35-labeled hERG radioligand.
Raab CE; Butcher JW; Connolly TM; Karczewski J; Yu NX; Staskiewicz SJ; Liverton N; Dean DC; Melillo DG
Bioorg Med Chem Lett; 2006 Mar; 16(6):1692-5. PubMed ID: 16377185
[TBL] [Abstract][Full Text] [Related]
19. Refining insights into high-affinity drug binding to the human ether-à-go-go-related gene potassium channel.
Hancox JC; James AF
Mol Pharmacol; 2008 Jun; 73(6):1592-5. PubMed ID: 18381562
[TBL] [Abstract][Full Text] [Related]
20. Computer simulations of structure-activity relationships for HERG channel blockers.
Boukharta L; Keränen H; Stary-Weinzinger A; Wallin G; de Groot BL; Aqvist J
Biochemistry; 2011 Jul; 50(27):6146-56. PubMed ID: 21657256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
